Chinese Medical Device Firms Including New Valve Medical and Reliant Heart Accelerate IPO Filings

　　【Pharmaceutical Network Industry DynamicsIn recent years, domestically produced innovative medical devices have entered a new phase of high-end and capitalization. At the same time, in order to accelerate the development of enterprises and further enhance competitiveness, many companies have begun to push for IPOs, aiming to obtain more funds to support subsequent research and development as well as market expansion. It is reported that only in the past month, a large number of companies such as NewMed, CH Biomedical, and Promisemed have entered the IPO stage.
 

Recently, NewMed submitted an IPO coaching filing report to the Shanghai Securities Regulatory Bureau. Public information shows that NewMed is a medical device company focusing on high-end cardiovascular interventional devices, with its core business centered on structural heart disease interventional products. Currently, the company has built a pipeline portfolio comprising one core product and eight products under development, among which the balloon-expandable transfemoral transcatheter aortic valve replacement product, Prizvalve, is its key project.
 

Notably, this shift to the A-share market marks the company's fourth attempt at accessing the capital market. It previously submitted listing applications to the Hong Kong Stock Exchange in August 2021, February 2022, and October 2022, all of which have since lapsed. If successful in its A-share IPO, the move will provide significant support for the company’s subsequent R&D investment, market expansion, and platform development, while also helping it align more closely with the domestic market and clinical needs.
 

On December 26, 2025, the Shanghai Stock Exchange website showed that the STAR Market IPO of Suzhou CH Biomedical Co., Ltd. has been accepted. According to the disclosure, it is an innovative medical device company with implantable artificial hearts as its core product at this stage.
 

This offering plans to raise 1.064 billion yuan, which will be used for the construction of the implantable left ventricular assist system production base project, the implantable left ventricular assist system research and development project - BrioVAD global clinical trial and registration project, the implantable left ventricular assist system research and development project - next-generation LVAS research and development project, and replenishment of working capital.
 

On December 26, 2025, Pouant (Hangzhou) Medical Technology Co., Ltd. successfully passed the review of the Beijing Stock Exchange, with Guotai Securities as the sponsor. The company focuses on the research, development, and production of medical devices for diabetes care, general drug delivery and infusion, and minimally invasive interventions, with its core product being insulin pen needles. In this IPO, it plans to raise 395 million yuan for projects such as the construction of an intelligent manufacturing production line for puncture interventional medical devices and the R&D and industrialization construction project for minimally invasive interventional medical devices.
 

On December 23, 2025, Hannuo Medical's STAR Market IPO was accepted. As a high-end innovative medical device enterprise, it focuses on technological innovation in the extracorporeal life support (ECLS) field, and its core product, the Lifemotion ECMO system, was launched in 2023. In this STAR Market IPO, the company plans to raise 1.062 billion yuan, which will be invested in the Hannuo Medical Research and Development Center Construction Project, Hannuo Medical Production Base Construction Project, Hannuo Medical Marketing Network Construction Project, and replenishment of working capital.
 

In addition to the aforementioned companies, a large number of medical enterprises have entered the IPO stage by the end of 2025. Swey Technology, a company in the ophthalmic OCT field, officially launched its IPO on December 11; Promisemed, a disposable endoscope enterprise, has also submitted its IPO coaching filing, and its IPO status has now been changed to "submitted for registration"...
 

Overall, the IPO pace of current medical device companies has significantly accelerated. In the future, this trend will continue to drive the technological iteration and commercialization of domestically produced devices and expedite the process of domestic substitution in the high-end market.
 

　　Disclaimer: In no event shall the information or opinions expressed in this article constitute investment advice to any person.